News
HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $28 Price Target
1 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Acelyrin Q4 EPS $(0.75) Beats $(0.99) Estimate
28 Mar 24
Earnings, Earnings Beats, News
Wells Fargo Maintains Equal-Weight on Acelyrin, Raises Price Target to $13
21 Mar 24
News, Price Target, Analyst Ratings
Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
20 Mar 24
Biotech, News, Health Care, Movers, General
HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $30 Price Target
20 Mar 24
News, Price Target, Reiteration, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $30 Price Target
12 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
11 Mar 24
Biotech, Equities, News, Health Care, General
Acelyrin Announces Top-line Results From Its Global Phase 2B/3 Trial Of Izokibep In Psoriatic Arthritis, Met The Primary Endpoint Of ACR50 At Week 16 With High Statistical Significance Versus Placebo
11 Mar 24
Biotech, News, Health Care, General
Acelyrin Announces Long-term 32-week Data From The Phase 2B Trial Of Izokibep In Hidradenitis Suppurativa Demonstrating Sustained Responses And Deepening Clinical Benefit
11 Mar 24
Biotech, News, Health Care, General
Press releases
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
27 Mar 24
M&A, News, Health Care, Financing, Press Releases, General
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
11 Mar 24
Health Care, Press Releases
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
11 Mar 24
Press Releases, General